MedTrace Logo

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

NCT06917001 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-08-28

No results posted yet for this study

Summary

The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are:

Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.

Conditions

  • Dengue Fever

Interventions

DRUG

Resomelagon

Resomelagon 100mg, orally, once daily.

DRUG

Placebo

Placebo

OTHER

Standard Treatment

Hydration and symptomatic therapy as indicated for Dengue fever.

Sponsors & Collaborators

  • Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)

    collaborator UNKNOWN

  • Federal University of Minas Gerais

    lead OTHER

Principal Investigators

  • Mauro M Teixeira, MD PhD · Federal University of Minas Gerais

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06917001 on ClinicalTrials.gov